Review Article
Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal
Table 4
The influence of the duration of remission or previous therapy on the outcome after drug withdrawal.
| Author | Year | Disease | Drug | Length of previous remission in the different groups | Length of previous therapy with the drug in the different groups | Better outcome at withdrawal after longer remission/therapy |
| Riis et al. [9] | 1973 | UC | Sulphasalazine | 12–24 months versus >24 months | | No |
| Dissanayake and Truelove [10] | 1973 | UC | Sulphasalazine | 1–3 years versus >3 years | | No |
| Ardizzone et al. [11] | 1999 | UC | 5-ASA | 1-2 years versus >2 years | | Yes |
| Hawthorne et al. [12] | 1992 | UC | Azathioprine | Continuous analysis | | Yes; |
| Fraser et al. [26] | 2002 | UC | Azathioprine | | <2 years versus 2–4 years vs. >4 years | No |
| Cassinotti et al. [27] | 2009 | UC | Azathioprine | | 3–6 months versus 48 months | Yes |
| O’Donoghue et al. [13] | 1978 | CD | Azathioprine | <1 years versus 1-2 years versus >2 years | <1 years versus 1-2 years versus >2 years | No |
| Bouhnik et al. [16] | 1996 | CD | Azathioprine | 6 months–4 years versus >4 years | | Yes |
| Kim et al. [28] | 1999 | CD | 6-Mercaptopurine | | <1 year versus 1-2 years versus 2-3 years versus >3 years | No |
| Holtmann et al. [29] | 2006 | CD | Azathioprine/6-mercaptopurine | | <3 years versus 3-4 years versus >4 years | No |
| Treton et al. [18] | 2009 | CD | Azathioprine | | Median 62 months versus 80 months | No |
|
|